GO:0071604 transforming growth factor beta production: Cytokine Secretion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071604 (transforming growth factor beta production) describes the appearance of TGF-beta family cytokines (TGF-B1, TGF-B2, TGF-B3) through biosynthesis or secretion after cellular stimulation.
• TGF-beta production is a master driver of tissue fibrosis in kidney, heart, and vasculature, making it a central target for antifibrotic research.
• TGF-beta directs immune cell fate decisions, including IgA class switching in human B cells, linking production levels to mucosal immunity.
• TGF-beta-3 acts as a mitogen for retinal progenitor cells, showing that production of distinct family members controls neural development.
• TGF-beta stimulates secondary cytokine production (e.g., interleukin-11) in periodontal and gingival fibroblasts, amplifying inflammatory and fibrotic circuits.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of TGF-beta production genes in disease.
Description
Transforming growth factor beta (TGF-beta) production (GO:0071604) is the biological process by which cells generate and release TGF-beta family cytokines, including TGF-B1, TGF-B2, and TGF-B3, in response to stimulation. This process encompasses both biosynthesis and secretion, leading to increased intracellular or extracellular levels of these potent signaling molecules. Because TGF-beta cytokines are pleiotropic regulators of cell growth, differentiation, and extracellular matrix deposition, their production is tightly linked to development, immunity, and tissue homeostasis. Dysregulated TGF-beta production is a hallmark of chronic fibrotic diseases affecting the kidney, heart, and vasculature. In the kidney, TGF-beta and Smad signaling drive mesangial expansion and tubulointerstitial fibrosis, making production levels a key research focus. In the heart, TGF-beta1 induction promotes cardiac fibrosis and adverse remodeling after injury. Vascular hypertrophy in hypertension is also associated with TGF-beta1 production, linking this process to hemodynamic disease. Beyond fibrosis, TGF-beta production controls specialized immune functions such as IgA switching in human B cells, underscoring its broad physiological importance. In the nervous system, TGF-beta-3 production supports retinal progenitor cell proliferation, revealing roles in neural development. Inflammatory microenvironments further modulate TGF-beta production; for example, crosstalk between interleukin-1 receptor-like 1 and TGF-beta receptor signaling promotes renal fibrosis. Additionally, TGF-beta stimulates interleukin-11 production in periodontal ligament and gingival fibroblasts, demonstrating how TGF-beta production amplifies downstream cytokine networks. For researchers, GO:0071604 provides a defined framework to study the synthesis, secretion, and regulation of TGF-beta cytokines, enabling mechanistic dissection of fibrosis, immunity, and development using CRISPR-based models.
transforming growth factor beta production At A Glance
| GO ID | GO:0071604 |
|---|---|
| GO term | transforming growth factor beta production |
| Ontology | biological_process |
| Synonym | TGF-beta production; TGFbeta production; TGFb production; TGF-B production; transforming growth factor-beta production; transforming growth factor-beta secretion |
| Major function | Biosynthesis and secretion of TGF-beta family cytokines (TGF-B1, TGF-B2, TGF-B3) following cellular stimulation |
| Family members | TGF-B1, TGF-B2, TGF-B3 |
| Cellular outcome | Increased intracellular or extracellular levels of TGF-beta cytokines |
| Disease relevance | Tissue fibrosis (kidney, heart, vasculature), immune dysregulation, developmental disorders |
| Research focus | Regulation of production, secretion, and downstream signaling in fibrosis and immunity |
What Is GO:0071604?
GO:0071604 (transforming growth factor beta production) is defined as the appearance of any member of the transforming growth factor-beta family of cytokines due to biosynthesis or secretion following a cellular stimulus, resulting in an increase in its intracellular or extracellular levels. The family includes TGF-B1, TGF-B2, and TGF-B3. This term covers both the biosynthetic production and the secretion of these cytokines, distinguishing it from downstream signaling events.
Why Is transforming growth factor beta production Important in Cell Biology?
GO:0071604 is critically important because TGF-beta production is a central node in the pathogenesis of fibrosis, immune regulation, and developmental processes. Dysregulated TGF-beta production drives kidney, cardiac, and vascular fibrosis, making it a prime therapeutic target. In immunity, TGF-beta production controls IgA class switching, linking it to mucosal defense. In development, TGF-beta-3 production supports retinal progenitor proliferation. Moreover, TGF-beta production amplifies inflammatory circuits by inducing secondary cytokines such as interleukin-11. Understanding this process is essential for designing interventions that modulate TGF-beta levels without disrupting homeostasis.
• TGF-beta production is a master driver of kidney fibrosis through Smad signaling.
• Cardiac fibrosis is induced by TGF-beta1 production after injury.
• Vascular hypertrophy in hypertension is associated with TGF-beta1 production.
• TGF-beta directs IgA switching in human B cells, impacting mucosal immunity.
• TGF-beta-3 production is mitogenic for retinal progenitor cells, influencing neural development.
• TGF-beta stimulates interleukin-11 production in periodontal fibroblasts, amplifying inflammation.
• Crosstalk between IL-1 receptor-like 1 and TGF-beta receptor signaling promotes renal fibrosis.
• TGF-beta production is a therapeutic target for antifibrotic strategies.
• Dysregulated TGF-beta production contributes to chronic tissue remodeling.
• CRISPR models enable causal dissection of TGF-beta production genes in disease.
What Happens During transforming growth factor beta production?
Cellular Stimulation and Transcriptional Activation
In simple terms: A cell receives a signal that tells it to start making TGF-beta.
TGF-beta production begins when cells receive stimuli such as injury, inflammation, or mechanical stress, leading to transcriptional activation of TGFB1, TGFB2, or TGFB3 genes. In kidney diseases, TGF-beta and Smad signaling are activated in response to injury, driving increased production. Cardiac fibrosis is initiated by TGF-beta1 induction following stress. Vascular hypertrophy in hypertension involves TGF-beta1 production as a response to hemodynamic overload. This step is regulated by multiple signaling pathways that converge on TGF-beta gene promoters.
Biosynthesis and Intracellular Processing
In simple terms: The cell builds the TGF-beta protein and prepares it for release.
After transcription, TGF-beta mRNA is translated into precursor proteins that undergo proteolytic processing and dimerization. The biosynthetic pathway ensures that mature TGF-beta cytokines are produced and available for secretion. In renal fibrosis, this biosynthetic upregulation leads to increased intracellular TGF-beta levels. Similarly, in periodontal fibroblasts, TGF-beta stimulates the production of interleukin-11, indicating active biosynthesis and secretion of cytokines. The production process includes both intracellular accumulation and extracellular release.
Secretion and Extracellular Accumulation
In simple terms: The cell releases TGF-beta outside, where it can act on other cells.
Secretion of TGF-beta results in increased extracellular levels, allowing the cytokine to bind receptors on target cells. In IgA switching, TGF-beta secreted by B cells directs class switching, demonstrating functional secretion. In retinal progenitor cells, TGF-beta-3 is secreted and acts as a mitogen. In fibrotic kidney, secreted TGF-beta drives Smad signaling and matrix deposition. The balance between intracellular and extracellular TGF-beta is critical for its biological effects.
Amplification via Downstream Cytokine Networks
In simple terms: TGF-beta can trigger more cytokine production, creating a feedback loop.
TGF-beta production often amplifies inflammatory and fibrotic circuits by inducing secondary cytokines. For example, TGF-beta stimulates interleukin-11 production by human periodontal ligament and gingival fibroblasts. Crosstalk between interleukin-1 receptor-like 1 and TGF-beta receptor signaling promotes renal fibrosis, enhancing TGF-beta production and its effects. This amplification loop sustains fibrosis and chronic inflammation.
Key Genes Involved in GO:0071604 transforming growth factor beta production
The following genes and proteins are central to transforming growth factor beta production (GO:0071604), based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Encodes TGF-beta1, a major profibrotic cytokine | Central to kidney, cardiac, and vascular fibrosis |
| TGFB2 | Encodes TGF-beta2, involved in development and fibrosis | Studied in tissue remodeling and fibrosis |
| TGFB3 | Encodes TGF-beta3, regulates progenitor proliferation | Mitogenic for retinal progenitor cells |
| SMAD2 | Transduces TGF-beta signals to nucleus | Key mediator of fibrosis |
| SMAD3 | Transduces TGF-beta signals to nucleus | Key mediator of fibrosis |
| SMAD4 | Co-SMAD, partners with SMAD2/3 | Central to TGF-beta signaling |
| IL1RL1 | Interleukin-1 receptor-like 1, crosstalks with TGF-beta receptor | Promotes renal fibrosis |
| IL11 | Interleukin-11, induced by TGF-beta | Amplifies fibrosis in periodontal tissues |
| TGFBR1 | TGF-beta receptor type I | Mediates signaling and feedback |
| TGFBR2 | TGF-beta receptor type II | Mediates signaling and feedback |
| LTBP1 | Latent TGF-beta binding protein | Regulates TGF-beta secretion and activation |
| COL1A1 | Collagen type I alpha 1, downstream of TGF-beta | Marker of fibrosis |
| ACTA2 | Alpha smooth muscle actin, myofibroblast marker | Induced by TGF-beta in fibrosis |
| CTGF | Connective tissue growth factor, downstream mediator | Promotes fibrosis |
| SERPINE1 | Plasminogen activator inhibitor-1, TGF-beta target | Involved in matrix accumulation |
| JUN | Transcription factor activated by TGF-beta | Regulates gene expression in fibrosis |
| FOS | Transcription factor activated by TGF-beta | Regulates gene expression in fibrosis |
How Is transforming growth factor beta production Regulated?
TGF-beta production is regulated at multiple levels, including transcriptional activation by injury and inflammatory stimuli, post-transcriptional processing, and secretion. In kidney diseases, TGF-beta and Smad signaling form a positive feedback loop that sustains production. Cardiac fibrosis involves induction of TGF-beta1 by mechanical and neurohumoral factors. Vascular hypertrophy in hypertension is associated with increased TGF-beta1 production. Crosstalk between interleukin-1 receptor-like 1 and TGF-beta receptor signaling enhances renal fibrosis, indicating that inflammatory pathways modulate TGF-beta production. Additionally, TGF-beta itself stimulates interleukin-11 production, creating an amplification loop. These regulatory mechanisms are targets for antifibrotic therapies.
transforming growth factor beta production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB1 | Kidney fibrosis, cardiac fibrosis, vascular hypertrophy | Knockout or overexpression in renal/cardiac cells |
| TGFB3 | Retinal progenitor proliferation | Overexpression in retinal progenitor cells |
| IL1RL1 | Renal fibrosis | Knockout in kidney fibroblasts |
| IL11 | Periodontal inflammation and fibrosis | Knockdown in gingival fibroblasts |
| SMAD3 | Tissue fibrosis | Point mutation or knockout in fibrotic models |
TGF-beta Production in Kidney Fibrosis
TGF-beta production is a central driver of kidney fibrosis. TGF-beta and Smad signaling promote mesangial expansion and tubulointerstitial fibrosis in chronic kidney disease. Crosstalk between interleukin-1 receptor-like 1 and TGF-beta receptor signaling further promotes renal fibrosis, highlighting the interplay between inflammatory and profibrotic pathways. Targeting TGF-beta production is a promising antifibrotic strategy.
TGF-beta Production in Cardiac and Vascular Fibrosis
In the heart, TGF-beta1 production induces cardiac fibrosis and adverse remodeling after injury. In hypertension, TGF-beta1 production is associated with vascular hypertrophy, contributing to vascular stiffness and end-organ damage. These findings link TGF-beta production to cardiovascular pathology.
TGF-beta Production in Immune Regulation and Mucosal Immunity
TGF-beta directs IgA switching in human B cells, a process dependent on TGF-beta production and secretion. This function connects TGF-beta production to mucosal immunity and immune tolerance. Dysregulated production may contribute to autoimmune and inflammatory conditions.
TGF-beta Production in Neural Development and Inflammation
TGF-beta-3 is mitogenic for rat retinal progenitor cells, indicating a role for TGF-beta production in neural development. In periodontal tissues, TGF-beta stimulates interleukin-11 production by fibroblasts, amplifying inflammation and tissue remodeling. These examples illustrate the diverse biological contexts of TGF-beta production.
From transforming growth factor beta production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFB1 reduce fibrosis? | TGFB1 knockout in renal or cardiac cells |
| Does a specific SMAD3 mutation alter TGF-beta production? | SMAD3 point mutation knock-in |
| Can TGFB3 overexpression drive progenitor proliferation? | TGFB3 overexpression in retinal progenitor cells |
| Does IL1RL1 crosstalk enhance TGF-beta production? | IL1RL1 knockout in kidney fibroblasts |
| Does TGF-beta induce IL11 in periodontal cells? | IL11 knockdown in gingival fibroblasts |
| Can tagged TGFB1 track secretion? | Tagged knock-in of TGFB1 |
How to Study the transforming growth factor beta production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Secreted TGF-beta protein levels | Quantifying production in conditioned media |
| Western blot | Intracellular TGF-beta protein levels | Assessing biosynthesis |
| RT-qPCR | TGFB1/2/3 mRNA levels | Transcriptional regulation |
| RNA-seq | Global transcriptome changes | Pathway analysis in fibrosis |
| Phospho-Smad immunoblot | TGF-beta signaling activation | Functional downstream assays |
| Luciferase reporter | TGF-beta promoter activity | Regulation of production |
| CRISPR knockout | Gene function loss | Causal testing in fibrosis |
| Overexpression | Gain-of-function effects | Testing TGFB3 in progenitors |
Quantifying TGF-beta Production
ELISA and Western blot are standard methods to measure TGF-beta protein levels in cell lysates and conditioned media, allowing assessment of intracellular and secreted pools. These methods are used to evaluate production changes in fibrosis models.
Transcriptional Analysis of TGF-beta Genes
RT-qPCR and RNA-seq measure mRNA levels of TGFB1, TGFB2, and TGFB3, providing insights into transcriptional regulation of production. These approaches are applied in kidney and cardiac fibrosis studies.
Signaling Pathway Assays
Phospho-Smad immunoblotting and luciferase reporter assays assess TGF-beta signaling activity downstream of production. These methods help link production to functional outcomes in fibrosis.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and overexpression models enable causal testing of genes involved in TGF-beta production. These models are used to dissect fibrosis and immune regulation mechanisms.
How CRISPR Can Be Used to Study GO:0071604 transforming growth factor beta production
Knockout
CRISPR knockout of TGFB1, TGFB2, or TGFB3 eliminates production of specific TGF-beta family members, enabling causal tests of their roles in fibrosis and immunity. Knockout of SMAD3 disrupts downstream signaling and feedback on production. Knockout of IL1RL1 reduces crosstalk-driven renal fibrosis.
Point Mutation
Point mutations in SMAD3 or TGFB1 can mimic disease-associated variants, allowing precise dissection of how specific residues affect TGF-beta production and signaling. These models are valuable for studying fibrotic mechanisms.
Knock-in
Tagged knock-in of TGFB1 (e.g., with fluorescent or affinity tags) enables real-time tracking of production and secretion in live cells. Knock-in of disease variants in SMAD3 helps model fibrosis.
Overexpression
Overexpression of TGFB3 in retinal progenitor cells demonstrates its mitogenic role. Overexpression of TGFB1 in cardiac or renal cells models fibrosis and tests antifibrotic interventions.
How EDITGENE Supports transforming growth factor beta production Research
Researchers studying transforming growth factor beta production-related genes often need to determine whether a candidate gene is causally involved in cytokine biosynthesis, secretion, or downstream fibrosis. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models for such mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for transforming growth factor beta production research.
Frequently Asked Questions About transforming growth factor beta production
What is GO:0071604 transforming growth factor beta production?
GO:0071604 is a Gene Ontology biological process term describing the appearance of TGF-beta family cytokines (TGF-B1, TGF-B2, TGF-B3) due to biosynthesis or secretion following cellular stimulation, leading to increased intracellular or extracellular levels.
What genes are involved in transforming growth factor beta production?
Key genes include TGFB1, TGFB2, TGFB3, SMAD2, SMAD3, SMAD4, and regulators such as IL1RL1 and IL11.
How is TGF-beta production regulated?
TGF-beta production is regulated transcriptionally by injury and inflammation, and through feedback loops involving Smad signaling and crosstalk with interleukin-1 receptor-like 1.
What diseases are linked to TGF-beta production?
TGF-beta production is linked to kidney fibrosis, cardiac fibrosis, vascular hypertrophy, and immune dysregulation such as IgA switching.
How can I study TGF-beta production in the lab?
Common methods include ELISA, Western blot, RT-qPCR, phospho-Smad immunoblotting, and CRISPR knockout or overexpression models.
What is the role of TGF-beta in kidney fibrosis?
TGF-beta and Smad signaling promote mesangial expansion and tubulointerstitial fibrosis, making production a therapeutic target.
Does TGF-beta control IgA switching?
Yes, TGF-beta directs IgA switching in human B cells, linking production to mucosal immunity.
What is the function of TGF-beta-3 in retinal progenitors?
TGF-beta-3 is mitogenic for rat retinal progenitor cells, indicating a role in neural development.
Can TGF-beta induce other cytokines?
Yes, TGF-beta stimulates interleukin-11 production by human periodontal ligament and gingival fibroblasts.
What CRISPR models are available for TGF-beta production research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening models for genes involved in TGF-beta production.
Conclusion
GO:0071604 (transforming growth factor beta production) is a fundamental biological process encompassing the biosynthesis and secretion of TGF-beta family cytokines. Its dysregulation drives fibrosis in kidney, heart, and vasculature, and it plays key roles in immune regulation and neural development. Understanding the regulatory mechanisms and causal genes involved is essential for developing targeted therapies. CRISPR-based models, combined with quantitative methods, provide powerful tools to dissect this process and identify new therapeutic opportunities.
References
- 1. Ren LL et al.. 2023. Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities.. Chem Biol Interact 369:110289 PMID: 36455676
- 2. Wang W et al.. 2005. Transforming growth factor-beta and Smad signalling in kidney diseases.. Nephrology (Carlton) 10(1):48-56 PMID: 15705182
- 3. Lijnen PJ et al.. 2000. Induction of cardiac fibrosis by transforming growth factor-beta(1).. Mol Genet Metab 71(1-2):418-35 PMID: 11001836
- 4. Agrotis A et al.. 1995. Transforming growth factor-beta 1 and the development of vascular hypertrophy in hypertension.. Blood Press Suppl 2:43-8 PMID: 7582073
- 5. Zhu X et al.. 2023. Crosstalk between Interleukin-1 Receptor-Like 1 and Transforming Growth Factor-β Receptor Signaling Promotes Renal Fibrosis.. Am J Pathol 193(8):1029-1045 PMID: 37236504
- 6. van Vlasselaer P et al.. 1992. Transforming growth factor-beta directs IgA switching in human B cells.. J Immunol 148(7):2062-7 PMID: 1347548
- 7. Anchan RM et al.. 1995. Transforming growth factor-beta-3 is mitogenic for rat retinal progenitor cells in vitro.. J Neurobiol 28(2):133-45 PMID: 8537820
- 8. Yashiro R et al.. 2006. Transforming growth factor-beta stimulates interleukin-11 production by human periodontal ligament and gingival fibroblasts.. J Clin Periodontol 33(3):165-71 PMID: 16489941
